Abstract： The purpose of this study was to investigate the therapeutic efficacy and short-term outcome of recombinant human brain natriuretic peptide combined with Entresto in patients with chronic heart failure. A retrospective study was conducted on 74 patients with chronic heart failure between January 2018 and January 2020, who were assigned to the study group and the control group, for comparison of the therapeutic efficacy, cardiac function-related indicators, adverse reactions and major adverse cardiac events (MACE) between groups. The study found significant difference in therapeutic efficacy between the two groups (94.59% vs 75.68%, P<0.05) . There were differences in levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP) , protein of growth-stimulation expressed gene 2 (ST2) , cardiac troponin I (CTn-I) , and 6-minute walk distance after the treatment in either group ( P<0.05) , and the improvement in these indicators was more favorable in the study group compared with the control group ( P<0.05) . The two groups were comparable in general in adverse reactions ( P=0.684) , but differed significantly in MACE (13.5% vs. 37.8%, P<0.05) . In summary, recombinant human brain natriuretic peptide combined with Entresto can improve the therapeutic efficacy and short-term outcome in patients with chronic heart failure.